Presently, over 65 companies claim to offer drug repurposing-related services<Roots>

Repurposing of marketed / shelved / pipeline candidates for the treatment of diseases (different from original target indications) has emerged as a viable business strategy. The rising popularity of this approach can further be attributed to various benefits, such as reduced development timelines, decreased investments and relatively higher success rates (considering that the safety profiles of such candidates have already been established).

To order this 250+ page report, which features 100+ figures and 140+ tables, please visit this –

The USD 1.2 billion (by 2030) financial opportunity within the drug repurposing service providers market has been analyzed across the following segments:
 Type of Repurposing Approaches
 Disease-centric approach
 Target-centric approach
 Drug-centric approach
 Therapeutic Area
 Same Therapeutic Area
 Different Therapeutic Area
 Type of Drug Molecule
 Biologics
 Small Molecule
 Key Geographical Region
 North America
 Europe
 Asia-Pacific

The Drug Repurposing Service Providers Market, 2020-2030 report features the following companies, which we identified to be key players in this domain:
 Auxillis Pharma
 ChemBio Discovery Solutions
 Excelra
 GVK Bio
 Iris Pharma
 Lantern Pharma
 PanXome
 Pharmacelera
 Physiogenex
 Smart Pharma
 Socium
 SOM Biotech

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Market Landscape

5. Role of Non-Profit / Academic Organizations

6. Company Profiles

7. Partnerships

8. Big Pharma Initiatives

9. Case Study: Discontinued Drug Development Programs

10. Cost Saving Analysis

11. Market Forecast and Opportunity Analysis

12. Covid-19 Impact on Drug Repurposing Service Providers Market

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415 

Leave a Reply

Your email address will not be published. Required fields are marked *